Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2024-03-19
Target enrollment:
Participant gender:
Summary
This study is a open-lable , single arm，single center, phase II clinical study. Target
population is patients with high-risk Soft tissue sarcoma. Study objective is to compare the
efficacy and safety of camrelizumab in combination with Liposome doxorubicin and Ifosfamide
in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.